GLP-1 receptor agonists have already redrawn the treatment of diabetes and obesity; now evidence hints their effects may reach mental health. A register-based study in The Lancet Psychiatry by researchers at Karolinska Institutet, the University of Eastern Finland and Griffith University analysed Swedish national registers from 2009 to 2022, covering nearly 100,000 people with depression or anxiety disorders, of whom more than 20,000 had used GLP-1 medications.
Users of these drugs experienced less hospital care and less sickness absence due to mental ill-health. Semaglutide, the active substance in Ozempic and Wegovy, showed the clearest association, with significant reductions in psychiatric hospitalisation and sickness absence; liraglutide showed a smaller association, while other agents in the class, such as exenatide and dulaglutide, showed no significant effect, a gradient that loosely tracks the drugs' potency.
The authors underline that observational data of this kind demonstrate association, not causation: people who tolerate and persist with newer GLP-1 drugs may differ systematically from those who do not. Randomised controlled trials are needed to establish whether the drugs directly improve mental health. But with metabolic and psychiatric illness so often entangled, the findings mark out an important new research frontier.